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Abstract
Background: To characterize healthcare resource utilization and costs in patients with metastatic lung cancer
receiving chemotherapy in the US.
Methods: Using data from a large private multi-payer health insurance claims database (2000-2006), we identified
all patients beginning chemotherapy for metastatic lung cancer. Healthcare resource use (inpatient, outpatient,
medications) and costs were tallied over time from date of therapy initiation ("index date”) to date of disenrollment
from the health plan (in most instances, presumably due to death) or the end of the study period, whichever
occurred first. Healthcare utilization and costs were characterized using Kaplan-Meier sample average methods.
Results: The study population consisted of 4068 patients; mean (SD) age was 65 (11) years. Over a median follow-
up of 334 days, study subjects averaged 1.5 hospital admissions, 8.9 total inpatient days, and 69 physician office
and hospital outpatient visits. Mean (95% CI) cumulative total healthcare costs were $125,849 ($120,228, $131,231).
Costs of outpatient medical services and inpatient care constituted 34% and 20% of total healthcare costs,
respectively; corresponding estimates for outpatient chemotherapy and other medication were 22% and 24%.
Conclusion: Our study sheds additional light on the burden of metastatic lung cancer among patients receiving
chemotherapy, in terms of total cost thru end of life as well as component costs by setting and type of service,
and may be useful in informing medical resource allocation in this patient population.
Background
Lung cancer is a common and aggressive disease that is
usually diagnosed in relatively late stages with little or
no chance of cure. The American Cancer Society esti-
mated that there would be about 219,440 new cases of
lung cancer in the US in 2009, accounting for approxi-
mately 15% of all new cancer diagnoses [1]. More than
45% of all patients with incident lung cancer present
with advanced disease [2]; median survival time among
these patients ranges from 8 to 13 months [3]. There
are about 160,000 deaths annually due to lung cancer in
the US, surpassing the total number of deaths from
breast, prostate, and colorectal cancer combined. In
2004, costs of care in patients with lung cancer were
estimated to account for approximately 20% ($4.2 bil-
lion) of all Medicare expenditures for the treatment of
cancer, a figure that is greater than the estimated total
cost of treatment among patients with colorectal or
prostate cancer ($2 billion) [4].
Metastatic lung cancer is difficult to treat. Systemic
chemotherapy–often in combination with targeted
therapies, such as bevacizumab–is currently the pre-
ferred treatment strategy [5] for lung cancer patients
with non-squamous histology. However, such treatment
typically produces only modest improvements in survival
and symptom palliation. Median survival among patients
receiving bevacizumab–the most efficacious treatment at
this time–is about 12 months.
Because the benefits of chemotherapy for metastatic
lung cancer – in terms of both extensions in life expec-
tancy and enhanced quality of life – are typically limited,
the cost of such treatment (as well as associated follow-
on care) is an especially important consideration in an
era of increased emphasis on achieving an acceptable
balance between the costs and benefits of medical inter-
ventions [6]. While a few retrospective longitudinal stu-
dies [7-11] have estimated the cost of metastatic lung
cancer in the US, these studies employed varied designs
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ease definitions, and measure of healthcare costs), did
not track lifetime healthcare resource use and costs, or
did not analyze cost components by setting or type of
service. Up-to-date data on resource use and costs
among patients with metastatic lung cancer – overall
and by constituent component – thus may help inform
current decision-making about the optimal allocation of
healthcare resources.
Contemporary data on resource use and costs in this
patient population also may help inform cost-effective-
ness evaluations of new strategies for the prevention,
screening, and treatment of early stage and metastatic
lung cancer; such information increasingly plays a role
in regulatory and reimbursement decision making [6].
Evaluations of early stage interventions, for example,
typically consider the economic consequences of disease
progression (i.e., treatment failure), which may be char-
acterized using data on levels of resource use and costs
among patients with metastatic lung cancer. We there-
fore used a large US private health insurance claims
database to estimate cumulative healthcare resource uti-
lization and costs through end of life in patients receiv-
ing chemotherapy for metastatic lung cancer.
Methods
Data Source
Data for this study were obtained from the MarketScan
Commercial Claims and Encounters Database, a large
private health insurance claims database, and spanned
the period January 1, 2000 through December 31, 2006.
The database is comprised of medical (i.e., facility and
professional service) and outpatient pharmacy claims
from employer-sponsored health insurance plans cover-
ing more than 10 million persons annually, including
employees as well as their spouses and dependents. The
plans provide health benefits under a number of differ-
ent products, including fee-for-service and capitated
(full, partial) systems. Plan members reside throughout
the US; approximately 10% are aged 65 years or older.
Data available for each facility and professional-service
claim include date and place of service, diagnoses (in
International Classification of Diseases, Ninth Edition,
Clinical Modification [ICD-9-CM] format), procedures
performed/services rendered (in Health Care Financing
Administration Common Procedure Coding System
Level II [HCPCS], Common Procedural Terminology
[CPT], ICD-9-CM, and Uniform Bill-92 [UB-92] for-
mats), and quantity of services (professional-service
claims only). Data available for each retail pharmacy
claim include the drug dispensed (in National Drug
Code [NDC] format), dispensing date, quantity dis-
pensed, and number of days of therapy supplied. All
claims include paid (i.e., reimbursed) amounts, including
patient deductibles, copays, and/or coinsurance
amounts. Selected demographic and eligibility informa-
tion is also available for persons in the database, includ-
ing age, sex, geographic location, coverage type, and the
start and end dates of health insurance coverage.
Patient-level data can be arrayed chronologically to pro-
vide a detailed longitudinal profile of all medical and
pharmacy services received.
All patient-identifying information has been either
f u l l ye n c r y p t e do rr e m o v e df r o mt h ed a t a b a s e ;i ti s
therefore compliant with the Health Insurance Portabil-
ity and Accountability Act of 1996 and federal guidance
on Public Welfare and the Protection of Human Sub-
jects. Per the Code of Federal Regulations (45 CFR 46
§46.101), IRB review was not needed for a study of this
nature, since “. . . subjects cannot be identified, directly
or through identifiers linked to the subjects . . .”.
Study Subjects
The study population consisted of all patients aged ≥ 18
years who initiated chemotherapy for metastatic lung
cancer between January 1, 2000 and December 31, 2006,
and who met all other inclusion criteria. Subjects were
selected for inclusion in the study population as follows.
First, we identified all patients who had two or more
healthcare encounters (on different days) with a diagno-
sis of lung cancer (ICD-9-CM 162.x, V10.1x) during the
period of interest; all such patients were designated as
having “lung cancer”. Second, from among these
patients, we identified all those who also had two or
more encounters with a diagnosis of distant secondary
malignant neoplasm (ICD-9-CM 196.2, 196.5, 196.8,
197.1-199.0) during this period; this subgroup of
patients was designated as having “metastatic lung can-
cer”. (We required two or more encounters for both
lung cancer and metastatic disease to increase the speci-
ficity of our algorithm [i.e., reduce the number of false-
positives].) Third, from among the subgroup of patients
with metastatic lung cancer, we identified all those with
any evidence of receipt of chemotherapy based on a
procedure code for chemotherapy administration or
receipt of a chemotherapy agent (codes available upon
request), beginning 45 days prior to the date of the ear-
liest encounter with a diagnosis of secondary malignant
neoplasm. (A 45-day window was employed to capture
instances where chemotherapy might have been initiated
prior to the first notation of metastatic disease on a
health insurance claim.) The date of initial receipt of
chemotherapy was designated the “index date”.
To minimize the possibility of including patients who
may have received chemotherapy for primary tumors
other than lung cancer, we excluded all patients with
two or more encounters with a diagnosis of a primary
malignant neoplasm other than lung cancer (ICD-9-CM
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prior to their first evidence of metastatic disease, unless
the site of the other primary neoplasm and the site of
metastases were the same (e.g., malignant neoplasm of
bone [170.0] and metastasis to bone [198.5]). (The last
exclusion was used to account for instances where a site
of metastatic involvement might have been miscoded as
a primary tumor.) The only exception was patients with
malignant neoplasm of the skin, whom we retained in
the sample because the skin is not a site of metastatic
involvement in lung cancer. To ensure completeness in
case ascertainment, we also excluded patients if they
were not continuously eligible for comprehensive health
benefits during the 12-month period preceding their
index date.
Follow-Up
Follow-up began on the index date and ended with dis-
enrollment from the health plan (in most instances, pre-
sumably due to death) or the end of the study period,
whichever occurred first.
Measures
Healthcare utilization was assessed in terms of the per-
centage of patients receiving inpatient services, outpati-
ent services, and outpatient medications (i.e., drugs
administered in an outpatient setting or dispensed at an
outpatient pharmacy), and corresponding levels of care
provided. Healthcare costs were estimated using paid
amounts, and were characterized on an overall basis and
by component of care (i.e., inpatient and outpatient ser-
vices, outpatient medications). Utilization and costs of
outpatient services were further stratified by setting of
care (i.e., emergency room, physician office, hospital
outpatient, home health/hospice/skilled nursing facility
[SNF], and other), and by type of service (e.g., evaluation
and management, laboratory, radiology diagnostic, etc.)
within selected settings, as feasible. Utilization and costs
of medications were tallied on an overall basis as well as
for distinct medication groups. Cost of chemotherapy
administration was tallied in the outpatient services
category.
Analyses
Characteristics of study subjects were examined, includ-
ing age, geographic region, payer, prevalence of selected
pre-existing comorbidities, and healthcare expenditures
up to 12 months preceding the index date. Age, geo-
graphic region of residence, and payer type were ascer-
tained as of the index date. Comorbidities were
ascertained based on the presence of relevant diagnosis
codes during the history period.
Cumulative total healthcare utilization and costs were
tallied for each patient on a daily basis from the index
date through the end of follow up. Mean cumulative uti-
lization and costs were calculated using Kaplan-Meier
Sample Average (KMSA) methods. Using this technique,
the follow-up period for each patient was partitioned
into one-month intervals and Kaplan-Meier estimates of
the probability of survival and continued health plan
enrollment to the beginning of each interval were calcu-
lated. Expected utilization and associated costs of care
were then calculated as the sum of the Kaplan-Meier
estimates of the probability of survival to the beginning
of each interval multiplied by corresponding estimates
of utilization and costs respectively during the interval
conditional on survival to the beginning of the interval
[12]. Survival probabilities were calculated using dates of
disenrollment, as this was assumed to occur primarily as
a result of death in this patient population; subjects who
were observed through the end of the study period (i.e.,
December 31, 2006) were censored as of this date.
Ninety-five percent confidence intervals (95% CIs) were
calculated for total costs using techniques of nonpara-
metric bootstrapping [13]. Significance testing was not
performed, as there were no a priori hypotheses. Cumu-
lative total healthcare costs also were estimated focusing
on patients who were not censored, and thus for whom
claims data were available from their date of diagnosis
through date of death (i.e., plan disenrollment); compo-
nent costs were described among these patients as well.
Results
Patient Characteristics
The study population consisted of 4068 patients; sub-
jects excluded due to failure to meet study entry criteria
are provided in the Additional File 1. Mean (SD) age
was 65 (11) years; about 84% of patients were older than
55 years (Table 1). Mean (SD) healthcare costs up to 12
months preceding the index date were estimated
$28,562 ($31,136). Mean (SD) duration of follow-up was
500 (488) days (median = 334 days or ~ 11 months).
Healthcare Utilization
Seventy-two percent of patients were admitted to an
acute-care hospital at least once; the mean number of
hospital admissions was 1.5, and the mean number of
total inpatient days was 8.9 (Table 2). Patients also aver-
aged 41.5 physician office visits, 1.6 emergency room
visits, 18.2 hospital outpatient visits, 4.7 home health/
hospice/SNF visits, and 10.1 other outpatient encoun-
ters. In addition to evaluation and management services,
use of outpatient services was highest for radiology diag-
nostic services (91%), followed by laboratory (82%),
mental health services (68%), anesthesia and invasive
procedures (63%), radiation therapy (55%), and supplies
(52%). Patients averaged 39.7 medication prescriptions
during follow-up. Use of outpatient medication was
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and antidepressants (89%), followed by anti-emetics
(85%), anti-infectives (74%), gastrointestinal drugs (other
than anti-emetics) (57%), and cardiovascular drugs
(53%). Fewer than one-half of study subjects received
fluids and electrolytes (49%), erythropoietin stimulating
agents (ESAs) (46%), blood products and anticoagulants
(34%), granulocyte colony stimulating factors (29%), and
bisphosphonates (18%), respectively.
Healthcare Costs
Mean (95% CI) cumulative healthcare costs averaged
$125,849 ($120,228, $131,231) per patient over a mean
follow-up period of 500 days (Figure 1). Outpatient care
and inpatient care constituted 34% and 20% of total
healthcare costs, respectively; corresponding estimates
for outpatient chemotherapy and other medication were
22% and 24% (Table 3). Cumulative healthcare costs
($131,344) among non-censored patients (n = 776) were
Table 1 Demographic and clinical characteristics of study
subjects with metastatic lung cancer receiving
chemotherapy
Parameter Value
n = 4068
Age (n,%)
18-34 20 0.5
35-44 108 2.7
45-54 513 12.6
55-64 1,481 36.4
> = 65 1,946 47.8
Geographic region (n,%)
Northeast 538 13.2
Northcentral 1,249 30.7
South 2,071 50.9
West 208 5.1
Payer type (n,%)
HMO 81 2.0
Indemnity 1,814 44.6
PPO 1,210 29.7
POS 941 23.1
Other 21 0.5
Comorbidities (n,%)
Cerebrovascular Disease 426 10.5
Coronay heart disease 910 22.4
Heart failure 66 1.6
Peripheral arterial disease 165 4.1
Diabetes 808 19.9
Kidney Disease 60 1.5
Liver Disease 272 6.7
Respiratory Disease 2,384 58.6
Health care expenditures prior to index date (mean, SD)
-365 days 28,562 31,136
Table 2 Utilization of healthcare among patients with
metastatic lung cancer receiving chemotherapy
Value
n = 4068
Inpatient, mean
Acute hospital
Admissions (#) 1.5
Days (#) 8.9
Outpatient Services, mean
Physician Office (#) 41.5
Emergency Room (#) 1.6
Hospital Outpatient (#) 18.2
Home Health (#) 4.7
Other (#) 10.1
Pharmacy Prescriptions (#), mean 39.7
Inpatient, n (%)
Acute hospital 2,933 (72.1%)
Outpatient Services*, n (%)
Emergency Room 2,532 (62.2%)
Physician Office/Hospital Outpatient
Evaluation and Management 3,947 (97.0%)
Laboratory 3,331 (81.9%)
Radiology Diagnostic 3,691 (90.7%)
Radiology Therapeutic 2,241 (55.1%)
Nuclear Medicine 1,826 (44.9%)
Anesthesia and invasive procedures 2,581 (63.4%)
Blood & Transfusion 338 (8.3%)
Physical & Occupational Therapy 402 (9.9%)
Medical & Surgical Supplies 2,104 (51.7%)
Mental health-care 2,772 (68.1%)
Other 134 (3.3%)
Chemo administration 3,943 (96.9%)
Subtotal 4,032 (99.1%)
Home Health/Hospice/Skilled Nursing 2,200 (54.1%)
Other 3,314 (81.5%)
Total 4,053 (99.6%)
Medication, n (%)
Chemotherapy 4,068 (100.0%)
G-CSF 1,159 (28.5%)
ESAs 1,859 (45.7%)
Pain, sedatives, antidepressants 3,629 (89.2%)
Anti-infectives 2,991 (73.5%)
Anti-emetics 3,445 (84.7%)
Bisphosphonates 721 (17.7%)
Biologics 186 (4.6%)
Gastrointestinal 2,337 (57.4%)
Electrolytes, Caloric, Water 1,981 (48.7%)
Cardiovascular 2,161 (53.1%)
Blood products & Anticoagulants 1,393 (34.2%)
Other 3,976 (97.7%)
Total 4,068 (100.0%)
TOTAL 4,068 (100.0%)
*Other than medication administration
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About one-half (54%) of non-censored patients had total
costs less than $100,000 (Figure 2); outpatient and inpa-
tient services accounted for approximately one-half
(49%) of total healthcare costs, while chemotherapy
accounted for about 24% of the total. Among the
remaining non-censored patients with total costs
exceeding $100,000, corresponding figures were 50%
and 22%.
Discussion
Using a large private health insurance claims database,
we examined healthcare utilization and costs among
patients with metastatic lung cancer receiving che-
motherapy. Over a median follow-up of 334 days,
healthcare costs averaged $125,849 per patient. Che-
motherapy and other outpatient medication accounted
for 22% and 24% of total costs, respectively; other out-
patient and inpatient services accounted for 34% and
20% of these costs, respectively.
Comparisons of our findings with prior published esti-
mates are not straightforward due to differences in the
characteristics of patients included in these studies as
well as the methodologies employed. Also, more recent
increases in spending for advanced lung cancer may
reflect not only changes in detection and staging techni-
ques and management over time, but also increased use
of chemotherapy and targeted therapies. Three studies
were identified that examined the cost of advanced lung
cancer using the linked SEER-Medicare claims data
[4,7,9]. Yabroff and colleagues reported that costs of
care during the last year of life among patients with dis-
tant lung cancer averaged $85,392 (in 2010 USD); hospi-
talization costs were the single largest component of
cost among these patients. This estimate, however,
represented cost of patients dying from lung cancer as
well as those with lung cancer who died of other causes,
and did not include the cost of outpatient prescription
medications. Similar findings were reported by Lang et
al., who used linked SEER-Medicare claims data to esti-
mate costs among patients receiving first-line doublet
chemotherapy. Costs (excluding those of chemotherapy)
were reported to average $85,174 (in 2010 USD); hospi-
talization and physician visits represented more than
85% of the total. The third study [9] reported lifetime
costs among patients with distant disease to be $49,971
(in 2010 USD), but it should be noted that the study
was conducted in the mid-1990s. Other studies have
included one conducted at Henry Ford Health System,
which reported an estimate of $44,770 (in 2010 USD)
[8] for resources consumed between first progression
and death or end of study among patients with Stage
IIIB or IV disease who received chemotherapy; about
one-half of that cost was associated with inpatient
Figure 1 Cumulative costs among patients with metastatic lung cancer receiving chemotherapy.
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macy services. Finally, two additional studies reported
estimates of $40,226 (in 2010 USD) (excluding che-
motherapy costs) and $12,584 (in 2010 USD), respec-
tively, for the last six months of life among patients in a
Veteran Affairs medical center [10] and in the terminal
phase of their disease [11], respectively. The majority of
published studies did not track the full complement of
lifetime costs among patients with metastatic lung can-
cer. We believe this is one of the primary reasons why
our estimate of mean healthcare costs ($125,849) is sub-
stantially higher than those previously published. Prior
studies also did not report on the individual compo-
nents of healthcare utilization and costs, which was an
important objective of our study.
Caution should be exercised in generalizing from the
results of our study to other patient populations and
settings. First, our study employed data from a large US
private health insurance database comprising informa-
tion from employer-sponsored health insurance plans
on resource utilization and costs of active employees,
early retirees, and their dependents along with Medi-
care-eligible retirees with employer-sponsored supple-
mental Medicare coverage. Because such persons may
differ systematically from other patients with metastatic
lung cancer (e.g., the elderly with traditional Medicare
fee-for-service coverage, and the uninsured, who are not
represented in our database)–in terms of health status
and/or levels of resource utilization and costs–findings
of similar analyses may differ in other patient popula-
tions. Second, our study used a novel algorithm for
patient selection, the accuracy of which is unknown.
Cooper and colleagues reported that the sensitivity and
positive predictive value of using ICD-9-CM diagnosis
codes with healthcare claims to identify patients with
distant metastatic lung cancer was 58.3% and 88.2%,
respectively, based on an analysis of Medicare claims
data and information from the Surveillance, Epidemiol-
ogy and End Results (SEER) program [14]. We note,
however, that while Cooper and colleagues required
only one Medicare claim with an ICD-9-CM code for
diagnosis of secondary malignant neoplasm (i.e., meta-
static disease), we required two such claims to increase
the specificity of our case-ascertainment methods. We
also note that the size and composition of the study
population was largely robust when employing alterna-
tive sample-selection criteria (e.g., excluding all patients
with evidence of multiple primary tumors, irrespective
of their relationship with the site of metastasis [3% of
study population]), and when considering other evidence
for lung cancer (e.g., chemotherapy regimen) among
patients with multiple documented primary tumor types.
However, because the study algorithms have not been
formally validated, their accuracy (and by implication,
any resultant bias) is unknown. Finally, because we
focused attention on the subgroup of patients with
metastatic lung cancer who received chemotherapy, the
results of our study may not be generalizable to all
patients with metastatic lung cancer, including those
who did not receive chemotherapy.
Several additional limitations of our study should be
noted. First, our case-finding algorithm may have missed
some patients receiving chemotherapy. It typically takes
one year or more for newly approved products to
Table 3 Cumulative cost of medical-care services among
patients with lung cancer receiving chemotherapy
Mean (USD)(%)
n = 4068
Inpatient
Acute hospital 24,619 19.6%
Outpatient Services*
Emergency Room 802 0.6%
Physician Office/Hospital Outpatient
Evaluation and Management 2,436 1.9%
Laboratory 1,227 1.0%
Radiology Diagnostic 6,881 5.5%
Radiology Therapeutic 6,054 4.8%
Nuclear Medicine 838 0.7%
All Surgery/Anesthesia 1,654 1.3%
Blood & Transfusion 144 0.1%
Physical & Occupational Therapy 143 0.1%
Medical & Surgical Supplies 697 0.6%
Chemo administration 2,054 1.6%
Mental health-care 25 0.0%
Other 14,274 11.3%
Subtotal 36,426 28.9%
Home Health/Hospice/Skilled Nursing 1,531 1.2%
Other 4,291 3.4%
Total 43,050 34.2%
Medication
Chemotherapy 27,924 22.2%
G-CSF 2,968 2.4%
ESAs 4,526 3.6%
Pain, sedatives, antidepressants 1,693 1.3%
Anti-infectives 345 0.3%
Anti-emetics 2,500 2.0%
Bisphosphonates 1,133 0.9%
Biologics 2,783 2.2%
Gastrointestinal 536 0.4%
Electrolytes, Caloric, Water 58 0.0%
Cardiovascular 606 0.5%
Blood products & Anticoagulants 976 0.8%
Other 12,132 9.6%
Total 58,179 46.2%
TOTAL 125,849 100.0%
*Other than medication administration
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billing purposes. During the intervening period, provi-
ders use nonspecific (or miscellaneous) codes that also
may be used for other drugs. Second, given the terminal
nature of metastatic lung cancer, health plan disenroll-
ment in this study was assumed to occur as a result of
death; disenrollment therefore was not treated as a “cen-
soring event.” Switching between health plans during
treatment for metastatic disease should be an infrequent
event. Third, as the perspective of our analysis was that
of a third-party payer, we included neither out-of-pocket
expenses and co-payments, nor indirect costs (i.e., the
value of morbidity- and mortality-related productivity
loss). Finally, we did not adjust payment amounts for
inflation using a general or medical price index (since it
may not be appropriate for this particular subset of
patients – in this particular subset of health plans –
who consumed specific healthcare services), and our
estimates thus reflect the experience of patients in our
sample from 2001 to 2006.
Conclusion
The results of our study suggest that the economic burden
of patients with metastatic lung cancer receiving che-
motherapy is substantial – exceeding $125,000. The
results of our study also suggest that the majority of costs
are associated with outpatient–rather than inpatient–care.
Such findings may be important in informing the overall
allocation of healthcare resources, in defining potential
cost savings from disease prevention, and in evaluating the
cost-effectiveness of new medical interventions.
Additional material
Additional file 1: Appendix. Table. “Sample attrition: Metastatic lung
cancer”.
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